An FDA reviewer recommended the agency approve Bristol-Myers Squibb's Avalide as a first-line treatment for hypertension, promoting it from its second-line status. The reviewer, whose work was posted on the FDA Web site ahead of an advisory panel meeting on the drug, said the treatment was "highly effective" in treating moderate to severe hypertension.

Related Summaries